IXC Insider Trading

Insider Ownership Percentage: 59.79%
Insider Buying (Last 12 Months): A$32,172.84
Insider Selling (Last 12 Months): A$0.00

Invex Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Invex Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Invex Therapeutics Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 04/12/2021 01:04 PM ET

This chart shows the closing price history over time for IXC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Invex Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/9/2024Megan BaldwinInsiderCancelled400,000A$0.08A$33,600.00
3/27/2024Thomas (Tom) DuthyInsiderTransfer285,661A$0.08A$21,424.58
8/24/2023Thomas (Tom) DuthyInsiderBuy178,738A$0.18A$32,172.84
See Full Table

SEC Filings (Institutional Ownership Changes) for Invex Therapeutics (ASX:IXC)

1.44% of Invex Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. The company is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. Invex Therapeutics Ltd was incorporated in 2019 and is based in Perth, Australia.
Read More on Invex Therapeutics

Today's Range

Now: N/A

50 Day Range


52 Week Range

Now: N/A



Average Volume


Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Invex Therapeutics?

Invex Therapeutics' top insider shareholders include:
  1. Megan Baldwin (Insider)
  2. Thomas (Tom) Duthy (Insider)
Learn More about top insider investors at Invex Therapeutics.